Ittigen, January 12, 2009 - Pevion Biotech today announces the appointment of Dr. Thomas P. Stauffer to the position of Chief Executive Officer of the company, effective January 1, 2009, succeeding Peter Klein. Prior to his appointment Dr. Stauffer served as COO of Pevion Biotech. In this function he managed the financial, intellectual property and legal issues of the company. Before joining the company, Dr. Thomas Stauffer served as an IP consultant for small and midsize biotechnology companies and built and managed a department for IP services at the Swiss Federal Institute of Intellectual Property. Dr. Stauffer holds a PhD from the Swiss Federal Institute of Technology and an MSc from the University of Zurich.
Dr. Peter Grogg, chairman of the company, stated: “Dr. Stauffer knows the vaccine field very well and has proven himself in the company. Therefore the Board of Pevion Biotech is firmly convinced that Dr. Stauffer will be able to move the company forward and advance the clinical development of Pevion Biotech’s vaccine candidates, thus generating economic value.”
About Pevion Biotech Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the preclinical and clinical development of vaccines to prevent/treat infectious diseases and cancer. For its vaccine development, the company uses its virosome-based technology which is already validated by two registered and marketed vaccines. The combination of this virosome technology with novel innovative antigens substantially reduces the known risk in biotechnological development and permits the targeting of diseases where so far no appropriate treatment is available. Pevion Biotech targets indications which represent major medical needs, including prophylactic or therapeutic vaccines against breast cancer, candidiasis, RSV and influenza. One virosome-based vaccine candidate is currently in clinical development. For further questions, please contact: Miriam Peters Tel: +41 31 550 44 01 miriam.peters@pevion.com www.pevion.com
